# A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

> **NCT03464097** · PHASE3 · TERMINATED · sponsor: **Celgene** · enrollment: 550 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ozanimod
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03464097
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-27
- **Primary completion:** 2024-10-03
- **Final completion:** 2024-10-03
- **Target enrollment:** 550 (ACTUAL)
- **Why stopped:** The study has terminated due to non-safety reasons; Business Objectives have changed.
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03464097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03464097, "A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03464097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*